{"filings":[{"id":1537076,"accession_number":"0001493152-26-032621","cik":1641631,"company_name":"Beyond Air, Inc.","ticker":"XAIR","form_type":"8-K","filed_at":"2026-07-09T13:20:14+00:00","items":["3.03","5.03","9.01"],"status":"ready","headline":"Beyond Air approves 1-for-20 reverse stock split to regain Nasdaq compliance","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Reverse stock split at 1-for-20 ratio, effective 12:01 a.m. ET on July 13, 2026.","Stockholders approved the split on June 18, 2026; Certificate of Amendment filed with Delaware on July 9, 2026.","Split intended to raise bid price above $1.00 to meet Nasdaq Listing Rule 5550(a)(2).","No change to authorized shares (500M common, 10M preferred) or par value; fractional shares rounded up.","Ticker symbol XAIR unchanged; new CUSIP 08862L301."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":5470000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":1304878,"accession_number":"0001493152-26-030305","cik":1641631,"company_name":"Beyond Air, Inc.","ticker":"XAIR","form_type":"8-K","filed_at":"2026-06-26T20:30:19+00:00","items":["2.02","5.03","7.01","9.01"],"status":"ready","headline":"Beyond Air reports 107% revenue growth in FY2026; guides $8M for CY2026, $16-18M for CY2027","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue FY2026 $7.7M (+107% YoY); Q4 $1.9M (+66%). Net loss per share ($4.01) vs ($13.77) prior year.","Cash $17.3M; long-term debt $21.6M; $18.2M available under equity line; net cash burn $19.1M in FY2026.","Guidance: CY2026 revenue $8M (~15% growth), CY2027 $16-18M (over 110% growth, includes Gen2 LungFit launch).","Leadership: CEO Robert Goodman (appointed March 2026), CFO Dan Moorhead (Jan 2026), Chairman Bob Carey.","Fiscal year changes from Mar 31 to Dec 31, effective Dec 31, 2026; transition report for 9 months ending Dec 31, 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":5470000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":1195199,"accession_number":"0001493152-26-029587","cik":1641631,"company_name":"Beyond Air, Inc.","ticker":"XAIR","form_type":"8-K","filed_at":"2026-06-22T20:15:30+00:00","items":["5.07","8.01"],"status":"ready","headline":"Beyond Air stockholders approve 1-for-20 reverse stock split to regain Nasdaq compliance","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Stockholders approved reverse split at special meeting June 18, 2026; 5,177,506 for, 1,222,793 against.","Board set ratio at 1-for-20, combining every 20 shares into 1 share of common stock.","Split intended to raise bid price above $1.00 to meet Nasdaq Bid Price Rule by July 31, 2026 deadline.","Company cautions that split may not be implemented or achieve desired compliance."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":5470000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":778921,"accession_number":"0001493152-26-026638","cik":1641631,"company_name":"Beyond Air, Inc.","ticker":"XAIR","form_type":"8-K","filed_at":"2026-06-01T20:30:41+00:00","items":["8.01","9.01"],"status":"ready","headline":"Beyond Air receives Nasdaq panel grant for continued listing; must meet bid price rule by July 31, 2026","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Nasdaq Hearings Panel granted continued listing subject to regaining Bid Price Rule compliance by July 31, 2026.","Company is fully compliant with all other continued listing requirements.","Special meeting of stockholders on June 18, 2026 to vote on reverse stock split proposal.","If approved, Board will determine reverse split ratio appropriate to facilitate bid price compliance."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":5470000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":94326,"accession_number":"0001493152-26-016855","cik":1641631,"company_name":"Beyond Air, Inc.","ticker":"XAIR","form_type":"8-K","filed_at":"2026-04-15T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Beyond Air receives Nasdaq delisting notice for bid price non-compliance; hearing requested","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Nasdaq Staff notified Beyond Air that its common stock failed to maintain minimum $1.00 bid price per Listing Rule 5550(a)(2).","Company timely requested a hearing on April 13, 2026; delisting action is stayed pending written Panel decision.","Hearing before Nasdaq Hearings Panel is scheduled for May 14, 2026.","There is no assurance the Panel will grant continued listing or that Beyond Air can regain compliance within any granted period."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":5470000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":94325,"accession_number":"0001493152-26-016172","cik":1641631,"company_name":"Beyond Air, Inc.","ticker":"XAIR","form_type":"8-K","filed_at":"2026-04-10T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Beyond Air receives Nasdaq delisting notice for bid price non-compliance; reverse stock split ineligible for cure period","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Nasdaq notified Beyond Air on Apr 7, 2026 that it fails Bid Price Rule; stock closed below $1 for 30 consecutive business days through Apr 6.","Company is ineligible for 180-day cure period due to 1-for-20 reverse stock split on July 14, 2025.","Beyond Air intends to request a hearing before Nasdaq Hearings Panel by Apr 14, 2026; request automatically stays delisting.","Common stock (XAIR) will continue trading on Nasdaq pending Panel decision; no assurance of regaining compliance.","Company considering options including another reverse stock split to regain compliance."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":5470000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":94324,"accession_number":"0001493152-26-014676","cik":1641631,"company_name":"Beyond Air, Inc.","ticker":"XAIR","form_type":"8-K","filed_at":"2026-04-01T23:59:59+00:00","items":["1.01","5.02","7.01","9.01"],"status":"ready","headline":"Beyond Air CEO Steve Lisi resigns; Robert Goodman appointed CEO effective March 27, 2026","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Steve Lisi resigned as CEO and director, effective March 27, 2026; no disagreement with the Company.","Robert Goodman, previously Chief Commercial Officer and director, appointed CEO effective March 27, 2026.","Lisi receives $650,000 severance over 12 months, 12 months of COBRA premiums, and accelerated vesting of all unvested equity.","Goodman has 25+ years in healthcare sales leadership; prior roles include BioTelemetry, Philips, Cardiocore, Thermo Fisher, and Pfizer."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":5470000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":106605,"accession_number":"0001493152-26-006708","cik":1641631,"company_name":"Beyond Air, Inc.","ticker":"XAIR","form_type":"8-K","filed_at":"2026-02-13T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Beyond Air Q3 revenue up 105% to $2.2M, net loss narrows; FY2026 guidance reaffirmed at $8-10M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $2.2M, up 105% YoY; gross profit $0.3M vs ($0.2M) gross loss prior year.","Net loss $7.3M ($0.85 loss per share) vs $13.0M ($2.96 loss) prior year.","Pro forma cash $22.3M, including Jan PIPE net proceeds of $4.5M; runway into CY2027.","Appointed Dan Moorhead CFO; Bob Carey appointed Board Chairman.","Binding LOI: XTL to acquire 85% of NeuroNOS; Beyond Air to receive up to $32.5M in cash, equity, milestones."],"consensus_eps_estimate":null,"consensus_eps_actual":-3.44,"consensus_revenue_estimate":null,"consensus_revenue_actual":5772000.0,"consensus_period":"2026-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":5470000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":106604,"accession_number":"0001493152-26-004741","cik":1641631,"company_name":"Beyond Air, Inc.","ticker":"XAIR","form_type":"8-K","filed_at":"2026-02-02T23:59:59+00:00","items":["5.07","9.01"],"status":"ready","headline":"Beyond Air stockholders elect directors, ratify auditor, approve equity plan at 2026 annual meeting","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["All six director nominees elected: Steven A. Lisi, Robert S. Goodman, Robert F. Carey, Dr. William Forbes, Yoori Lee, Erick J. Lucera.","Ratification of WithumSmith+Brown, PC as independent auditor for FY ending March 31, 2026: 4,086,430 for, 20,603 against, 114,375 abstain.","Eighth Amended and Restated 2013 Equity Incentive Plan approved, adding 850,000 shares for issuance; 1,119,142 for, 884,509 against.","Adjournment proposal not needed as sufficient votes were present to pass other proposals.","Quorum of 52.70% of outstanding shares represented at the meeting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":5470000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":106603,"accession_number":"0001493152-26-002884","cik":1641631,"company_name":"Beyond Air, Inc.","ticker":"XAIR","form_type":"8-K","filed_at":"2026-01-20T23:59:59+00:00","items":["1.01","3.02","8.01","9.01"],"status":"ready","headline":"Beyond Air raises $5M in private placement of stock and warrants at $1.272/unit","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Gross proceeds of $5.0M from sale of 3,930,818 shares (or pre-funded warrants) and five-year warrants at $1.147 strike.","Rodman & Renshaw acted as exclusive placement agent; proceeds for working capital and general corporate purposes.","Closing expected Jan 16, 2026; resale registration statement to be filed by Feb 4, 2026.","Offering includes 90-day lock-up on further equity issuance and six-month ban on variable rate transactions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":5470000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":106602,"accession_number":"0001493152-26-002292","cik":1641631,"company_name":"Beyond Air, Inc.","ticker":"XAIR","form_type":"8-K","filed_at":"2026-01-15T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"XTL to acquire 85% of Beyond Air's NeuroNOS for equity, $1M cash, up to $32.5M milestones","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["XTL acquires 85% of NeuroNOS for 19.9% of XTL's share capital, $1M cash, and up to $32.5M in milestone payments.","NeuroNOS platform targets core autism pathophysiology; two Nobel Laureates join scientific team.","NeuroNOS holds two FDA Orphan Drug Designations for Phelan-McDermid Syndrome and Glioblastoma.","Beyond Air becomes significant XTL shareholder, retains 15% of NeuroNOS; deal valued up to $32.5M."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":5470000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":122936,"accession_number":"0001493152-25-029637","cik":1641631,"company_name":"Beyond Air, Inc.","ticker":"XAIR","form_type":"8-K","filed_at":"2025-12-30T23:59:59+00:00","items":["1.01","5.02","8.01","9.01"],"status":"ready","headline":"Beyond Air appoints Dan Moorhead as CFO effective Jan 5, 2026; replaces interim CFO Duke Dewrell","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Salary set at $325k; eligible for discretionary bonus and equity participation.","Granted inducement stock option for 70,000 shares, vesting 25% on first anniversary and quarterly thereafter.","Moorhead most recently served as CFO of Zynex, Inc. until August 2025; brings 20+ years of finance leadership.","Duke Dewrell, who assumed CFO duties on an interim basis in November 2025, returns to controller role.","Appointment aligns with preparation for LungFit PH second-generation FDA approval and commercial launch."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":5470000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":122935,"accession_number":"0001493152-25-027289","cik":1641631,"company_name":"Beyond Air, Inc.","ticker":"XAIR","form_type":"8-K","filed_at":"2025-12-11T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Beyond Air appoints Denton Dewrell as principal financial officer and principal accounting officer","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Denton Dewrell, age 39, appointed as principal financial officer and accounting officer effective Dec 8, 2025.","He previously served as Global Controller since April 2025 and U.S. Controller from Aug 2024.","Base compensation remains $260,000 per year, participates in equity incentive plans of company and Beyond Cancer.","Mr. Dewrell is a CPA (Florida and Georgia) and holds a Master of Accounting from University of Florida.","Prior experience includes VP Corporate Controller at Updater Inc. and ten years at Ernst & Young LLP."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":5470000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":122934,"accession_number":"0001493152-25-025348","cik":1641631,"company_name":"Beyond Air, Inc.","ticker":"XAIR","form_type":"8-K","filed_at":"2025-11-28T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"CFO Doug Larson resigns; interim CFO Duke Drewell appointed","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Doug Larson resigns as CFO effective Dec 5, 2025 to pursue another opportunity; no disagreement with company.","Controller Duke Drewell assumes CFO responsibilities on interim basis; permanent successor search launched.","Larson will serve in advisory role through calendar year-end 2025 to ensure smooth transition."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":5470000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":122933,"accession_number":"0001493152-25-023538","cik":1641631,"company_name":"Beyond Air, Inc.","ticker":"XAIR","form_type":"8-K","filed_at":"2025-11-14T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Beyond Air Q2 revenue up 128% to $1.8M; net loss narrows; secures $32M financing","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $1.8M (+128% YoY); net loss ($7.9M) ($1.25/share) vs. ($13.4M) ($5.67/share).","Secured $32M capital ($12M note, 15%, 24-month maturity + $20M equity line); proforma cash $22.9M, runway into 2027.","Appointed Bob Goodman (Board member) as Interim CCO; David Webster departed.","Updated FY2026 revenue guidance to $8-$10M; achieved MDSAP certification; patent allowance for Gen2 LungFit PH.","International distribution network expanded to 35 countries; Phase 1a UNO trial completed with median survival >23 months."],"consensus_eps_estimate":null,"consensus_eps_actual":-2.75,"consensus_revenue_estimate":null,"consensus_revenue_actual":3578000.0,"consensus_period":"2026-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":5470000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":122932,"accession_number":"0001493152-25-020888","cik":1641631,"company_name":"Beyond Air, Inc.","ticker":"XAIR","form_type":"8-K","filed_at":"2025-11-05T23:59:59+00:00","items":["1.01","2.03","3.02","5.02","8.01","9.01"],"status":"ready","headline":"Beyond Air secures up to $32M in financing from Streeterville Capital","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Issued $12M promissory note with 15% annual interest; net proceeds ~$12M; $6M placed in restricted account.","Enters $20M equity line of credit (ELOC) to sell shares over 24 months; registration statement to be filed.","Amends loan with CEO Steven Lisi and director Robert Carey: additional $2M term loan, warrants at $1.95/share.","Board approves repricing of 726,618 options to $1.95, covering named executives and directors.","Proforma cash, equivalents, restricted cash, marketable securities of $22.9M as of Sept 30, 2025; runway into 2027."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":5470000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":139631,"accession_number":"0001493152-25-012866","cik":1641631,"company_name":"Beyond Air, Inc.","ticker":"XAIR","form_type":"8-K","filed_at":"2025-09-09T23:59:59+00:00","items":["1.01","3.02","7.01","9.01"],"status":"ready","headline":"Beyond Air receives ~$3.25M from warrant exercise; issues new warrants for 719,561 shares","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Gross proceeds ~$3.25M from immediate exercise of 1,439,126 existing warrants at reduced price of $2.21/share.","Issues new warrants to purchase up to 719,561 shares at $2.21, exercisable immediately, five-year term.","Placement agent Laidlaw receives 6.5% fee; net proceeds for clinical programs and working capital.","Closing expected September 9, 2025; resale registration statement to be filed by September 29, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":5470000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":139630,"accession_number":"0001493152-25-012825","cik":1641631,"company_name":"Beyond Air, Inc.","ticker":"XAIR","form_type":"8-K","filed_at":"2025-09-08T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"NeuroNOS (Beyond Air unit) receives FDA Orphan Drug Designation for BA-101 in glioblastoma","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA grants Orphan Drug Designation for BA-101, an investigational nNOS inhibitor, for treatment of glioblastoma.","This is NeuroNOS's second orphan drug designation; ODD provides tax credits, fee waivers, and 7-year market exclusivity if approved.","GBM median survival is <12 months; standard of care (surgery, radiation, temozolomide) is not curative.","NeuroNOS CEO cites urgent unmet need and NO modulation strategy; preclinical data showed NOS inhibition reduced GBM cell proliferation.","Company plans to advance BA-101 toward first-in-human studies."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":5470000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":139629,"accession_number":"0001641172-25-024647","cik":1641631,"company_name":"Beyond Air, Inc.","ticker":"XAIR","form_type":"8-K","filed_at":"2025-08-18T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Beyond Air Q1 revenue rises 157% to $1.8M; net loss narrows to $7.7M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $1.8M vs $0.7M YoY (+157%); gross profit $0.2M vs loss of $0.3M.","Net loss $(7.7)M ($1.53 per share) vs $(12.2)M ($5.32) in prior year.","Reaffirmed FY2026 revenue guidance of $12-$16M.","Cash $6.5M; net cash burn $4.7M in quarter; debt $11.6M.","Awarded Premier, Inc. group purchasing agreement covering >4,350 hospitals."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.53,"consensus_revenue_estimate":null,"consensus_revenue_actual":1760000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":5470000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":139628,"accession_number":"0001641172-25-018520","cik":1641631,"company_name":"Beyond Air, Inc.","ticker":"XAIR","form_type":"8-K","filed_at":"2025-07-10T23:59:59+00:00","items":["3.03","5.03","9.01"],"status":"ready","headline":"Beyond Air announces 1-for-20 reverse stock split to regain Nasdaq compliance","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Reverse stock split ratio 1-for-20, effective July 14, 2025.","Approved by stockholders on June 20, 2025; filed Certificate of Amendment on July 9, 2025.","Purpose: raise bid price above $1 to meet Nasdaq Listing Rule 5550(a)(2).","No change in authorized shares (500M common, 10M preferred) or par value.","Fractional shares rounded up; no cash in lieu."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":5470000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":157215,"accession_number":"0001641172-25-016406","cik":1641631,"company_name":"Beyond Air, Inc.","ticker":"XAIR","form_type":"8-K","filed_at":"2025-06-25T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Beyond Air shareholders approve reverse stock split at up to 1-for-50 ratio","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Shareholders approved reverse stock split ratio between 1-for-10 and 1-for-50, as determined by the Board.","Vote: 41,924,612 for, 6,382,862 against, 169,243 abstain; no broker non-votes.","Board has sole discretion to implement the split within one year of June 20, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":5470000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":157214,"accession_number":"0001641172-25-015650","cik":1641631,"company_name":"Beyond Air, Inc.","ticker":"XAIR","form_type":"8-K","filed_at":"2025-06-18T23:59:59+00:00","items":["2.02","5.02","8.01","9.01"],"status":"ready","headline":"Beyond Air Q4/FY2025 revenue $3.7M (+220% YoY); guides FY2026 $12-16M; filed PMA for LungFit PH II","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $3.7M for FY2025, up 220% YoY; net loss $46.6M ($0.69 per share).","Expects Q1 FY2026 revenue at least $1.7M, full FY2026 revenue $12-16M.","Submitted PMA supplement to FDA for next-gen LungFit PH II (smaller, transport-ready).","Appointed Robert Goodman to Board; international distribution covers 2B+ lives.","Cash $6.9M as of Mar 31, 2025; $2M additional debt financing post-quarter."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":5470000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":175564,"accession_number":"0001641172-25-001176","cik":1641631,"company_name":"Beyond Air, Inc.","ticker":"XAIR","form_type":"8-K","filed_at":"2025-03-28T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"Beyond Air subsidiary NeuroNOS secures $2M initial funding for autism therapy development","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["NeuroNOS raised $2M initial equity from private investors as part of a larger round up to $5M total.","Proceeds will accelerate preclinical development of a small-molecule drug targeting nitric oxide dysregulation in autism.","First-in-human clinical trial anticipated to begin in 2026; formulation optimization for subcutaneous injection underway.","After initial close, Beyond Air Ireland holds ~88% of NeuroNOS; would fall to ~75% if all $5M shares sold.","Drug stems from Hebrew University research showing NO inhibition improves autism phenotypes in animal models."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":5470000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":175563,"accession_number":"0001493152-25-010356","cik":1641631,"company_name":"Beyond Air, Inc.","ticker":"XAIR","form_type":"8-K","filed_at":"2025-03-14T23:59:59+00:00","items":["5.02","8.01","9.01"],"status":"ready","headline":"Beyond Air expands LungFit PH distribution to 4 new countries; director resigns","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Distribution agreements now cover France, Romania, Turkey and Morocco; total reaches 18 countries.","Initial international orders for LungFit PH systems received from four countries.","LungFit PH received CE Mark approximately 15 weeks ago; company expects faster international ramp than U.S.","Director Ron Bentsur resigned March 14, 2025; no disagreement with company or management.","Partners include EUROCARE (France), Medelart Healthcare (Turkey), Abb Neopuls (Romania), OXYPLUS (Morocco)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":5470000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":175562,"accession_number":"0001493152-25-006902","cik":1641631,"company_name":"Beyond Air, Inc.","ticker":"XAIR","form_type":"8-K","filed_at":"2025-02-14T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Beyond Air enters $35M ATM equity offering with BTIG; initially capped at $9.9M due to public float","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["ATM sales agreement with BTIG allows sale of up to $35M of common stock at Company's discretion.","Initial registered amount capped at $9,892,518 due to public float limitations; further sales require additional prospectus supplement.","Agent commission of up to 3% of gross proceeds; Company not obligated to sell any shares.","Agreement terminates upon sale of all shares or earlier termination; sales via 'at the market' methods."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":5470000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":175561,"accession_number":"0001493152-25-006892","cik":1641631,"company_name":"Beyond Air, Inc.","ticker":"XAIR","form_type":"8-K","filed_at":"2025-02-14T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Beyond Air Q3 FY2025 revenue $1.1M (+34% QoQ); cash burn $7.6M; CE Mark for LungFit PH in Europe","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $1.1M for Dec 31, 2024 quarter, up 34% from $0.8M in prior quarter and up from $0.4M YoY.","Cash, cash equivalents and marketable securities $10.9M; debt $11.8M; cash burn $7.6M in quarter.","Received CE Mark for LungFit PH in Europe; market authorization in Australia; initial shipments expected later 2025.","Six new U.S. hospital starts for LungFit PH in Q3; CE Mark triggers $1M milestone from Getz Healthcare due in Q4 FY2025.","NeuroNOS appointed Nobel laureate Prof. Roger D. Kornberg to Scientific Advisory Board."],"consensus_eps_estimate":-0.8721,"consensus_eps_actual":-0.64,"consensus_revenue_estimate":null,"consensus_revenue_actual":2553000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl+finnhub","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":5470000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":175560,"accession_number":"0001493152-25-005038","cik":1641631,"company_name":"Beyond Air, Inc.","ticker":"XAIR","form_type":"8-K","filed_at":"2025-02-05T23:59:59+00:00","items":["3.01","7.01","9.01"],"status":"ready","headline":"Beyond Air granted 180-day Nasdaq extension to Aug 4, 2025 to meet $1.00 bid price","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Second compliance period runs until August 4, 2025; must close at $1.00+ for 10 consecutive business days.","Company may effect a reverse stock split if needed to cure deficiency before deadline.","No immediate impact on listing; stock continues trading on Nasdaq Capital Market under XAIR.","First 180-day period ended Feb 4, 2025 without compliance; extension requested and approved."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":5470000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":192513,"accession_number":"0001493152-24-051040","cik":1641631,"company_name":"Beyond Air, Inc.","ticker":"XAIR","form_type":"8-K","filed_at":"2024-12-20T23:59:59+00:00","items":["4.01","9.01"],"status":"ready","headline":"Beyond Air dismisses Marcum, appoints WithumSmith+Brown as new auditor","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Audit Committee dismissed Marcum LLP as independent auditor effective Dec 17, 2024; dismissal not due to any disagreements.","Marcum's FY2024 and FY2023 reports included a going-concern uncertainty paragraph for FY2024.","No reportable events or disagreements occurred during the two most recent fiscal years.","WithumSmith+Brown, PC appointed as successor auditor for fiscal year ending March 31, 2025.","Marcum provided a letter to SEC agreeing with the Company's disclosures, dated Dec 20, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":5470000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":192512,"accession_number":"0001493152-24-049048","cik":1641631,"company_name":"Beyond Air, Inc.","ticker":"XAIR","form_type":"8-K","filed_at":"2024-12-06T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Beyond Cancer (Beyond Air) gets Israeli MoH approval for Phase 1b LV UNO + anti-PD-1 trial for solid tumors","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Israeli Ministry of Health approved Phase 1b trial of LV UNO in combination with anti-PD-1 therapy for solid tumors.","Trial will enroll up to 20 patients with unresectable solid tumors that progressed or were stable on PD-1 inhibitors.","Primary endpoint: objective response rate (ORR) and duration of response per RECIST v1.1; secondary immune-related response.","Four Israeli sites; patient screening Q1 2025; topline data expected second half of 2025.","Preclinical data showed single UNO dose increased PD-L1 expression and improved survival vs anti-PD-1 alone."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":5470000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":192511,"accession_number":"0001493152-24-048490","cik":1641631,"company_name":"Beyond Air, Inc.","ticker":"XAIR","form_type":"8-K","filed_at":"2024-12-03T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Beyond Air receives CE Mark for LungFit PH in Europe; triggers $1M milestone payment from Getz Healthcare","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["CE mark approval allows Beyond Air to market LungFit PH in the European Union and other recognizing countries.","$1 million milestone payment triggered from Asia-Pacific partner Getz Healthcare upon CE mark certification.","Indications include hypoxic respiratory failure in infants >34 weeks gestation and peri-/post-operative pulmonary hypertension in adults and children 0-17.","Partnership with Getz covers Australia, New Zealand, Thailand, Philippines, Taiwan, Hong Kong, Malaysia, Pakistan, Singapore, and Vietnam.","LungFit PH generates NO from ambient air via Ionizer technology, eliminating tanks and reducing hospital carbon footprint."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":5470000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":192510,"accession_number":"0001493152-24-047830","cik":1641631,"company_name":"Beyond Air, Inc.","ticker":"XAIR","form_type":"8-K","filed_at":"2024-11-26T23:59:59+00:00","items":["5.02","5.03","5.07","9.01"],"status":"ready","headline":"Beyond Air shareholders approve share increase to 500M and equity plan amendment; options repriced to $0.54","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Stockholders approved increase in authorized common shares from 100M to 500M (Proposal 5).","Seventh Amended 2013 Equity Incentive Plan approved, adding 3M shares; board gets repricing authority.","Board repriced 10,586,473 options with exercise prices >$0.54 down to $0.54, affecting named executives and directors.","CEO Steven Lisi holds 2.95M repriced options; CFO Douglas Larson 515K options repriced.","All director nominees elected; Marcum LLP ratified as auditor; say-on-pay passed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":5470000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":192509,"accession_number":"0001493152-24-046503","cik":1641631,"company_name":"Beyond Air, Inc.","ticker":"XAIR","form_type":"8-K","filed_at":"2024-11-18T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Beyond Air Q2 FY2025 revenue $0.8M (+17% QoQ); extends cash runway through June 2026","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $0.8M vs $0.2M YoY; cost of revenue $1.9M (depreciation & upgrade costs).","Cash, equivalents & marketable securities $28.4M; pro forma cash $18.5M after subsequent closings.","Retired $17.5M Avenue Capital debt; entered $11.5M loan (8% royalty on net sales from July 2026).","Completed $20.6M private placement with healthcare-focused funds and insiders.","Hospital contracts increased 60% in Q2; annualized contracted revenue $3.5M as of Oct 1, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.55,"consensus_revenue_estimate":null,"consensus_revenue_actual":1481000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":5470000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":192508,"accession_number":"0001493152-24-043852","cik":1641631,"company_name":"Beyond Air, Inc.","ticker":"XAIR","form_type":"8-K","filed_at":"2024-11-06T23:59:59+00:00","items":["1.01","2.03","3.02","9.01"],"status":"ready","headline":"Beyond Air secures $11.5M secured loan from CEO and director; issues warrants","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["$11.5M loan at 15% interest (3% cash, 12% PIK through June 2026); matures Oct 2034.","Warrants for 15,159,504 shares at $0.3793/share issued to CEO Steven Lisi and director Robert Carey.","Loan secured by substantially all assets; quarterly repayment from 8% royalty on net sales starts Oct 2026.","Independent board and investment bank approved the related-party transaction.","Proceeds used for working capital and refinancing; loan is full recourse upon maturity or default."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":5470000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":192507,"accession_number":"0001493152-24-040613","cik":1641631,"company_name":"Beyond Air, Inc.","ticker":"XAIR","form_type":"8-K","filed_at":"2024-10-09T23:59:59+00:00","items":["5.08"],"status":"ready","headline":"Beyond Air sets 2025 annual meeting for Dec 9, 2024; proposal deadline Oct 19","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["2025 Annual Meeting of Stockholders scheduled for December 9, 2024.","Stockholder proposals for inclusion in proxy materials due by October 19, 2024.","Director nominations and other business proposals must also be received by October 19, 2024.","Proposals received after deadline will be considered untimely.","Meeting time and location to be included in definitive proxy statement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":5470000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":192506,"accession_number":"0001493152-24-039221","cik":1641631,"company_name":"Beyond Air, Inc.","ticker":"XAIR","form_type":"8-K","filed_at":"2024-10-02T23:59:59+00:00","items":["1.01","2.03","3.02"],"status":"ready","headline":"Beyond Air enters $11.5M secured loan with CEO and director; 15% PIK interest, 8% royalty","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Term sheet for $11.5M secured loan from CEO Steven Lisi and director Robert Carey; 10-year term, 15% PIK interest through July 2026.","Royalty of 8% on net sales quarterly from July 2026 until repaid; secured by substantially all assets.","Warrants to purchase common stock at $0.3793 per share; definitive loan agreement expected by Oct 31, 2024.","Approved by independent disinterested directors after investment bank recommendation; interested parties involved."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":5470000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":208976,"accession_number":"0001493152-24-038433","cik":1641631,"company_name":"Beyond Air, Inc.","ticker":"XAIR","form_type":"8-K","filed_at":"2024-09-27T23:59:59+00:00","items":["1.01","3.02","8.01","9.01"],"status":"ready","headline":"Beyond Air raises $20.6M via private placement, retires $17.5M debt, extends cash runway to June 2026","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Sold 40,392,155 shares/pre-funded warrants at $0.51/$0.5099 per unit with warrants exercisable at $0.38 for 5 years.","Retired $17.5M Avenue Capital term loan with $17.85M payment, eliminating $12M in scheduled debt payments through June 2026.","Entered $11.5M royalty agreement (15% PIK interest) with insiders, payments based on LungFit PH sales starting July 2026.","Insiders contributed $2M to the offering; Avenue Capital invested $3.35M in equity.","Net proceeds used for working capital; Company expects cash runway to last through June 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":5470000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":208975,"accession_number":"0001493152-24-030972","cik":1641631,"company_name":"Beyond Air, Inc.","ticker":"XAIR","form_type":"8-K","filed_at":"2024-08-09T23:59:59+00:00","items":["2.02","3.01","5.02","9.01"],"status":"ready","headline":"Beyond Air reports Q1 revenue $0.7M, net loss $0.27/share; receives Nasdaq bid-price deficiency notice","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Revenue $0.7M, up 45% QoQ from $0.5M; net loss $12.2M ($0.27/share) vs $14.1M ($0.45) year ago.","Cash burn $13.1M; cash $21.4M; expects net cash burn <$30M in FY2025; breakeven target Q4 FY2026.","Nasdaq notice: bid price below $1.00 for 30 days; 180-day cure until Feb 4, 2025; may consider reverse split.","Amir Avniel appointed CEO of NeuroNOS (autism program); resigns as CBO and Board member effective Aug 15, 2024.","Revenue guidance >$10M for FY2025; commercial progress with LungFit PH in 55+ hospitals across 10 states."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":5470000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":226812,"accession_number":"0001493152-24-025433","cik":1641631,"company_name":"Beyond Air, Inc.","ticker":"XAIR","form_type":"8-K","filed_at":"2024-06-27T23:59:59+00:00","items":["1.01","2.02","2.03","9.01"],"status":"ready","headline":"Beyond Air reports FY2024 loss of $60.2M; cuts FY2025 revenue guidance to >$10M; extends loan interest-only period","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["FY2024 revenue $1.2M (vs. $0); net loss $60.2M ($1.82 loss per share).","FY2025 revenue guidance revised to >$10M from $12-16M; net cash burn expected <$30M.","Interest-only period on $40M term loan extended to June 30, 2025; further 12-month deferral contingent on $40M product revenue by Mar 2025.","Issued warrants to Avenue funds for 100,000 shares at $1.28, expiring June 2029.","Headcount reduced >20% since Jan 2024; new CCO David Webster appointed; cash and securities $34.5M."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":5470000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":226811,"accession_number":"0001493152-24-024277","cik":1641631,"company_name":"Beyond Air, Inc.","ticker":"XAIR","form_type":"8-K","filed_at":"2024-06-18T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Beyond Air appoints David Webster as Chief Commercial Officer effective July 8, 2024","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["David Webster appointed CCO, effective July 8, 2024, with over 20 years life sciences experience.","Previously CEO of Body Vision Medical; led commercialization of Lung Vision system.","Received inducement stock option for 125,000 shares, vesting over four years starting July 8, 2024.","Company expects Webster to drive LungFit PH market share gains and strengthen commercial team."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":5470000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":245771,"accession_number":"0001493152-24-010974","cik":1641631,"company_name":"Beyond Air, Inc.","ticker":"XAIR","form_type":"8-K","filed_at":"2024-03-22T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"Beyond Air raises $16M via registered direct offering of 9.6M shares & warrants at $1.66","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Gross proceeds of $16M from sale of 9,638,556 shares and warrants at combined price $1.66 per unit.","Net proceeds of ~$14.6M after fees; to fund commercial sales development, research, working capital.","Warrants exercisable at $2.25 per share for three years; callable if net sales ≥ $4.5M by Mar 31, 2025.","Certain directors and officers participated in the offering.","Roth Capital and Laidlaw & Company acted as co-placement agents."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":5470000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":245770,"accession_number":"0001493152-24-009982","cik":1641631,"company_name":"Beyond Air, Inc.","ticker":"XAIR","form_type":"8-K","filed_at":"2024-03-14T23:59:59+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"Beyond Air stockholders approve 3M share increase under 2013 Equity Plan","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["All 7 director nominees elected: Lisi, Avniel, Bentsur, Carey, Forbes, Lee, Lucera.","Ratification of Marcum LLP as independent auditor for fiscal 2024 approved (19.6M for, 74k against).","Sixth Amended 2013 Plan passed with 7.5M for, 2.3M against; broker non-votes 9.9M.","Plan authorizes additional 3,000,000 shares of common stock for issuance.","Total shares outstanding as of record date: 35,609,164; quorum 19,946,015 shares."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":5470000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":245769,"accession_number":"0001493152-24-008510","cik":1641631,"company_name":"Beyond Air, Inc.","ticker":"XAIR","form_type":"8-K","filed_at":"2024-03-01T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Beyond Air amends ATM equity agreement to remove Oppenheimer as sales agent","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Amendment No. 1 to Sales Agreement dated Feb 28, 2024 terminates Oppenheimer & Co. as agent.","Truist Securities remains the sole agent under the at-the-market offering program.","All other terms of the original February 2022 Sales Agreement stay in full force.","Oppenheimer's rights and obligations terminated subject to survival provisions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":5470000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":245768,"accession_number":"0001493152-24-007013","cik":1641631,"company_name":"Beyond Air, Inc.","ticker":"XAIR","form_type":"8-K","filed_at":"2024-02-16T23:59:59+00:00","items":["2.02","8.01","9.01"],"status":"ready","headline":"Beyond Air Q3 FY2024 net loss $16.2M; revenues $0.4M; FY2025 guidance reiterated $12-16M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $16.2M ($0.50 per share) vs $12.7M ($0.43) in Q3 FY2023; revenues $0.4M from zero prior year.","FY2025 revenue guidance reiterated at $12M-$16M; LungFit PH filter shipments up >100% QoQ.","PMA supplement for cardiac surgery label expansion accepted for filing and under FDA substantive review.","Cash, marketable securities $31.4M as of Dec 31, 2023; raised $5.5M via ATM to offset burn.","CMO Dr. Myers transitions to consultant effective Feb 16; CCO Duncan Fatkin leaves March 31."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.46,"consensus_revenue_estimate":null,"consensus_revenue_actual":689000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":5470000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":263242,"accession_number":"0001493152-23-041878","cik":1641631,"company_name":"Beyond Air, Inc.","ticker":"XAIR","form_type":"8-K","filed_at":"2023-11-17T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Beyond Air Q2 net loss widens to $16.2M; guides FY2025 revenue $12-$16M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $0.24M vs $0 prior year; net loss $16.2M ($0.51 loss per share) vs $12.0M ($0.40) prior year.","Cash burn $16.5M ($10.1M ex one-time); cash & securities $43.9M as of Sept 30, 2023.","FY2025 revenue guidance $12M-$16M; submitted PMA supplement for cardiac surgery; CE Mark expected H1 2024.","Beyond Cancer presented positive first-in-human UNO data at SITC; VCAP trial underway, data mid-2024.","Agreement with Getz Healthcare for Asia-Pacific; Vizient Innovative Technology contract awarded."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.96,"consensus_revenue_estimate":null,"consensus_revenue_actual":298000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":5470000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":280420,"accession_number":"0001493152-23-031919","cik":1641631,"company_name":"Beyond Air, Inc.","ticker":"XAIR","form_type":"8-K","filed_at":"2023-09-07T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Beyond Air Enters Distribution Agreement with Getz Healthcare for LungFit PH in Asia-Pacific","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Getz Healthcare to make $1,000,000 milestone payment upon CE mark certification of LungFit PH in Europe.","Beyond Air receives ongoing royalty payments on net sales starting at low double-digits and peaking at 20%.","Partnership covers 10 Asia-Pacific countries including Australia, New Zealand, Thailand, Philippines, Taiwan, Hong Kong, Malaysia, Pakistan, Singapore, and Vietnam.","BTIG, LLC acted as financial advisor to Beyond Air for the agreement.","LungFit PH is currently FDA-approved for neonates with hypoxic respiratory failure in the U.S. only."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":5470000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":280419,"accession_number":"0001493152-23-028715","cik":1641631,"company_name":"Beyond Air, Inc.","ticker":"XAIR","form_type":"8-K","filed_at":"2023-08-15T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Beyond Air Q1 FY2024 revenue $0.1M (first commercial); net loss $14.1M; secured $40M debt facility","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue of $0.1M from commercial LungFit PH sales; cost of revenue $0.3M.","Net loss $14.1M ($0.45 loss per share) vs $10.9M ($0.37) YoY; R&D $4.7M, G&A $10.9M.","Secured up to $40M debt financing from Avenue Capital; $17.5M drawn; cash $57M.","In excess of $1M annual commercial LungFit PH contracts; CE Mark expected by end 2023.","Agreed with FDA on VCAP study for 2023-24 winter; added nNOS program for autism."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.45,"consensus_revenue_estimate":null,"consensus_revenue_actual":59000.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":5470000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":298979,"accession_number":"0001493152-23-022243","cik":1641631,"company_name":"Beyond Air, Inc.","ticker":"XAIR","form_type":"8-K","filed_at":"2023-06-23T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Beyond Air reports $59.4M net loss for FY2023; secures $40M debt facility","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["GAAP net loss of $59.4M ($55.8M attributable, $1.86 per share) vs $43.2M ($1.68) prior year.","Cash, cash equivalents and marketable securities of $45.9M as of March 31, 2023.","Secured up to $40M debt financing from Avenue Capital; $17.5M funded at 12% or Prime+3.75% with warrants.","Completed phase 1 of LungFit PH commercial launch; shifted to phase 2; CE Mark and FDA label expansion expected in 2023.","Licensed nNOS inhibitors from Hebrew University for autism; first-in-human study planned in 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":5470000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":298978,"accession_number":"0001493152-23-021898","cik":1641631,"company_name":"Beyond Air, Inc.","ticker":"XAIR","form_type":"8-K","filed_at":"2023-06-20T23:59:59+00:00","items":["1.01","2.03","8.01","9.01"],"status":"ready","headline":"Beyond Air secures up to $40M debt financing; $17.5M funded at close","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["$17.5M advanced on June 15, 2023; up to $22.5M more available upon meeting milestones.","Interest rate: greater of WSJ Prime + 3.75% or 12.00%; maturity June 1, 2027.","Lenders granted warrants for 233,843 shares at $5.88 strike, expiring June 15, 2028.","Avenue has conversion right for up to $3M principal into stock at 130% of warrant exercise price.","Proceeds to support LungFit PH commercialization and clinical pipeline development."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":5470000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":319151,"accession_number":"0001493152-23-008876","cik":1641631,"company_name":"Beyond Air, Inc.","ticker":"XAIR","form_type":"8-K","filed_at":"2023-03-24T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Beyond Air loses appeal in Empery Suit; $7.4M collateral already posted","summary_kind":"llm","event_type":"litigation","confidence":"high","bullets":["Appellate Court affirmed prior judgment against Beyond Air in Empery Suit.","Company had posted $7.4M cash as collateral for supersedeas bond pending appeal.","Beyond Air says the adverse outcome will not materially impact liquidity or operations.","Lawsuit originally captioned Empery Asset Master, Ltd. et al. vs. AIT Therapeutics, Inc."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":5470000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":319150,"accession_number":"0001493152-23-008712","cik":1641631,"company_name":"Beyond Air, Inc.","ticker":"XAIR","form_type":"8-K","filed_at":"2023-03-23T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Beyond Air appoints Jeff Myers, M.D., Ph.D. as Chief Medical Officer effective March 27, 2023","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Dr. Myers brings ~15 years of biopharmaceutical executive experience and was previously a cardiothoracic surgeon at Massachusetts General Hospital.","Incumbent CMO Dr. Andrew Colin transitions to Senior Medical Director Global Clinical Leadership.","Dr. Myers received inducement option for 50,000 shares and inducement RSU for 50,000 shares, vesting over 4 and 5 years respectively.","Stock awards were approved by independent compensation committee under Nasdaq Listing Rule 5635(c)(4).","Beyond Air focuses on inhaled nitric oxide via LungFit platform for respiratory conditions and solid tumors through affiliate Beyond Cancer."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":5470000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":"2023-03-23T23:59:59+00:00|319150"}